Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Phosphorylation of Parkin at serine 65 is essential for its activation in vivo.

McWilliams TG, Barini E, Pohjolan-Pirhonen R, Brooks SP, Singh F, Burel S, Balk K, Kumar A, Montava-Garriga L, Prescott AR, Hassoun SM, Mouton-Liger F, Ball G, Hills R, Knebel A, Ulusoy A, Di Monte DA, Tamjar J, Antico O, Fears K, Smith L, Brambilla R, Palin E, Valori M, Eerola-Rautio J, Tienari P, Corti O, Dunnett SB, Ganley IG, Suomalainen A, Muqit MMK.

Open Biol. 2018 Nov 7;8(11). pii: 180108. doi: 10.1098/rsob.180108.

2.

Investigation into the Mechanism(s) That Leads to Platelet Decreases in Cynomolgus Monkeys During Administration of ISIS 104838, a 2'-MOE-Modified Antisense Oligonucleotide.

Narayanan P, Shen L, Curtis BR, Bourdon MA, Nolan JP, Gupta S, Hoffmaster C, Zhou F, Christian B, Schaubhut JL, Greenlee S, Burel SA, Witztum JL, Engelhardt JA, Henry SP.

Toxicol Sci. 2018 Aug 1;164(2):613-626. doi: 10.1093/toxsci/kfy119.

PMID:
29846725
3.

Development of phospho-specific Rab protein antibodies to monitor in vivo activity of the LRRK2 Parkinson's disease kinase.

Lis P, Burel S, Steger M, Mann M, Brown F, Diez F, Tonelli F, Holton JL, Ho PW, Ho SL, Chou MY, Polinski NK, Martinez TN, Davies P, Alessi DR.

Biochem J. 2018 Jan 2;475(1):1-22. doi: 10.1042/BCJ20170802.

4.

C-terminal phosphorylation of NaV1.5 impairs FGF13-dependent regulation of channel inactivation.

Burel S, Coyan FC, Lorenzini M, Meyer MR, Lichti CF, Brown JH, Loussouarn G, Charpentier F, Nerbonne JM, Townsend RR, Maier LS, Marionneau C.

J Biol Chem. 2017 Oct 20;292(42):17431-17448. doi: 10.1074/jbc.M117.787788. Epub 2017 Sep 7.

5.

Effect of Mesenchymal Stromal Cells on T Cells in a Septic Context: Immunosuppression or Immunostimulation?

Le Burel S, Thepenier C, Boutin L, Lataillade JJ, Peltzer J.

Stem Cells Dev. 2017 Oct 15;26(20):1477-1489. doi: 10.1089/scd.2016.0184. Epub 2017 Aug 28.

PMID:
28747098
6.

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis.

Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, Belkhir R, Soria JC, Laghouati S, Voisin AL, Fain O, Mékinian A, Coutte L, Szwebel TA, Dunogeant L, Lioger B, Luxembourger C, Mariette X, Lambotte O.

Eur J Cancer. 2017 Sep;82:34-44. doi: 10.1016/j.ejca.2017.05.032. Epub 2017 Jul 10.

PMID:
28646772
7.

The Distinct and Cooperative Roles of Toll-Like Receptor 9 and Receptor for Advanced Glycation End Products in Modulating In Vivo Inflammatory Responses to Select CpG and Non-CpG Oligonucleotides.

Paz S, Hsiao J, Cauntay P, Soriano A, Bai L, Machemer T, Xiao X, Guo S, Hung G, Younis H, Bennett CF, Henry S, Yun TJ, Burel S.

Nucleic Acid Ther. 2017 Oct;27(5):272-284. doi: 10.1089/nat.2017.0668. Epub 2017 Jun 12.

PMID:
28605247
8.

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.

Belkhir R, Burel SL, Dunogeant L, Marabelle A, Hollebecque A, Besse B, Leary A, Voisin AL, Pontoizeau C, Coutte L, Pertuiset E, Mouterde G, Fain O, Lambotte O, Mariette X.

Ann Rheum Dis. 2017 Oct;76(10):1747-1750. doi: 10.1136/annrheumdis-2017-211216. Epub 2017 Jun 9.

PMID:
28600350
9.

Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.

Henry SP, Narayanan P, Shen L, Bhanot S, Younis HS, Burel SA.

Nucleic Acid Ther. 2017 Aug;27(4):197-208. doi: 10.1089/nat.2017.0666. Epub 2017 May 25.

PMID:
28541820
10.

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette X, Voisin AL, Lambotte O.

Ann Rheum Dis. 2018 Mar;77(3):468-470. doi: 10.1136/annrheumdis-2016-210820. Epub 2017 Feb 27. No abstract available.

PMID:
28242618
11.

Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.

Crooke ST, Baker BF, Kwoh TJ, Cheng W, Schulz DJ, Xia S, Salgado N, Bui HH, Hart CE, Burel SA, Younis HS, Geary RS, Henry SP, Bhanot S.

Mol Ther. 2016 Oct;24(10):1771-1782. doi: 10.1038/mt.2016.136. Epub 2016 Jun 30.

12.

Dysfunction of the Voltage-Gated K+ Channel β2 Subunit in a Familial Case of Brugada Syndrome.

Portero V, Le Scouarnec S, Es-Salah-Lamoureux Z, Burel S, Gourraud JB, Bonnaud S, Lindenbaum P, Simonet F, Violleau J, Baron E, Moreau E, Scott C, Chatel S, Loussouarn G, O'Hara T, Mabo P, Dina C, Le Marec H, Schott JJ, Probst V, Baró I, Marionneau C, Charpentier F, Redon R.

J Am Heart Assoc. 2016 Jun 10;5(6). pii: e003122. doi: 10.1161/JAHA.115.003122.

13.

Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.

Prakash TP, Yu J, Migawa MT, Kinberger GA, Wan WB, Østergaard ME, Carty RL, Vasquez G, Low A, Chappell A, Schmidt K, Aghajan M, Crosby J, Murray HM, Booten SL, Hsiao J, Soriano A, Machemer T, Cauntay P, Burel SA, Murray SF, Gaus H, Graham MJ, Swayze EE, Seth PP.

J Med Chem. 2016 Mar 24;59(6):2718-33. doi: 10.1021/acs.jmedchem.5b01948. Epub 2016 Mar 9.

PMID:
26914862
14.

Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.

Burel SA, Hart CE, Cauntay P, Hsiao J, Machemer T, Katz M, Watt A, Bui HH, Younis H, Sabripour M, Freier SM, Hung G, Dan A, Prakash TP, Seth PP, Swayze EE, Bennett CF, Crooke ST, Henry SP.

Nucleic Acids Res. 2016 Mar 18;44(5):2093-109. doi: 10.1093/nar/gkv1210. Epub 2015 Nov 8.

15.

Vulnerability of Mediterranean ecosystems to long-term changes along the coast of Israel.

Kaniewski D, Van Campo E, Morhange C, Guiot J, Zviely D, Le Burel S, Otto T, Artzy M.

PLoS One. 2014 Jul 8;9(7):e102090. doi: 10.1371/journal.pone.0102090. eCollection 2014.

16.

Environmental roots of the late bronze age crisis.

Kaniewski D, Van Campo E, Guiot J, Le Burel S, Otto T, Baeteman C.

PLoS One. 2013 Aug 14;8(8):e71004. doi: 10.1371/journal.pone.0071004. eCollection 2013.

17.

Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.

Burel SA, Han SR, Lee HS, Norris DA, Lee BS, Machemer T, Park SY, Zhou T, He G, Kim Y, MacLeod AR, Monia BP, Lio S, Kim TW, Henry SP.

Nucleic Acid Ther. 2013 Jun;23(3):213-27. doi: 10.1089/nat.2013.0422.

PMID:
23692080
18.

Unique O-methoxyethyl ribose-DNA chimeric oligonucleotide induces an atypical melanoma differentiation-associated gene 5-dependent induction of type I interferon response.

Burel SA, Machemer T, Ragone FL, Kato H, Cauntay P, Greenlee S, Salim A, Gaarde WA, Hung G, Peralta R, Freier SM, Henry SP.

J Pharmacol Exp Ther. 2012 Jul;342(1):150-62. doi: 10.1124/jpet.112.193789. Epub 2012 Apr 13.

19.

[Telemedicine and nursing practices in teledialysis].

Bougeard D, Le Sann K, Domalain M, Burel S, Le Goff G.

Soins. 2010 Nov;(750):43-4. French.

PMID:
21155312
20.

[Nursing in teledialysis].

Moraux M, Le Sann K, Burel S.

Soins. 2007 Oct;(719 Suppl):S10-1. French. No abstract available.

PMID:
18050867
22.

Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.

Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A, Hines R, Akashi K, Zhang DE.

Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17186-91. Epub 2004 Nov 29.

23.

The fusion protein AML1-ETO in acute myeloid leukemia with translocation t(8;21) induces c-jun protein expression via the proximal AP-1 site of the c-jun promoter in an indirect, JNK-dependent manner.

Elsässer A, Franzen M, Kohlmann A, Weisser M, Schnittger S, Schoch C, Reddy VA, Burel S, Zhang DE, Ueffing M, Tenen DG, Hiddemann W, Behre G.

Oncogene. 2003 Aug 28;22(36):5646-57.

PMID:
12944913
24.

AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations.

Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ, Burel SA, Lagasse E, Weissman IL, Akashi K, Zhang DE.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10398-403.

25.

Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation.

Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE.

Mol Cell Biol. 2001 Aug;21(16):5577-90.

26.

AML1 and AML1 fusion protein AML1-ETO in myeloid gene regulation and leukemogenesis.

Zhang DE, Burel S, Zhou L, Hetherington CJ, Yuan Y.

Blood Cells Mol Dis. 2001 Mar-Apr;27(2):368-76. No abstract available.

PMID:
11259158

Supplemental Content

Support Center